Diagnostics (Jun 2023)

Inflammatory Biomarkers Affecting Survival Prognosis in Patients Receiving Veno-Venous ECMO for Severe COVID-19 Pneumonia

  • Željka Drmić,
  • Ivan Bandić,
  • Sonja Hleb,
  • Andrea Kukoč,
  • Sanja Sakan,
  • Nataša Sojčić,
  • Darko Kristović,
  • Verica Mikecin,
  • Ivana Presečki,
  • Zrinka Šafarić Oremuš,
  • Nikola Bradić,
  • Jasminka Peršec,
  • Andrej Šribar

DOI
https://doi.org/10.3390/diagnostics13132203
Journal volume & issue
Vol. 13, no. 13
p. 2203

Abstract

Read online

Severe COVID-19 pneumonia in which mechanical ventilation is unable to achieve adequate gas exchange can be treated with veno-venous ECMO, eliminating the need for aggressive mechanical ventilation which might promote ventilator-induced lung injury and increase mortality. In this retrospective observational study, 18 critically ill COVID-19 patients who were treated using V-V ECMO during an 11-month period in a tertiary COVID-19 hospital were analyzed. Biomarkers of inflammation and clinical features were compared between survivors and non-survivors. Survival rates were compared between patients receiving ECMO and propensity matched mechanically ventilated controls. There were 7 survivors and 11 non-survivors. The survivors were significantly younger, with a higher proportion of females, higher serum procalcitonin at ICU admission, and before initiation of ECMO they had significantly lower Murray scores, PaCO2, WBC counts, serum ferritin levels, and higher glomerular filtration rates. No significant difference in mortality was found between patients treated with ECMO compared to patients treated using conventional lung protective ventilation. Hypercapnia, leukocytosis, reduced glomerular filtration rate, and increased serum ferritin levels prior to initiation of V-V ECMO in patients with severe COVID-19 pneumonia may be early warning signs of reduced chance of survival. Further multicentric studies are needed to confirm these findings.

Keywords